Mirum Pharmaceuticals (MIRM) Accounts Payables (2018 - 2026)

Mirum Pharmaceuticals' Accounts Payables history runs 9 years deep, the most recent figure standing at $59.4 million for Q1 2026.

• On a quarterly basis, Accounts Payables rose 410.34% year-over-year to $59.4 million in Q1 2026; TTM through Mar 2026 was $59.4 million, a 410.34% increase from a year earlier, with the FY2025 full-year figure at $9.6 million, down 34.23% from the prior year.
• Accounts Payables advanced to $59.4 million in Q1 2026 per MIRM's latest filing, from $9.6 million in the prior quarter.
• Across five years, Accounts Payables topped out at $59.4 million in Q1 2026 and bottomed at $4.9 million in Q1 2022.
• The 5-year median for Accounts Payables is $9.8 million (2024), against an average of $13.4 million.
• Across the five-year window, Accounts Payables tumbled 34.23% in 2025 and surged 410.34% in 2026, its largest moves.
• Year by year, Accounts Payables stood at $8.7 million in 2022, then fell by 14.66% to $7.4 million in 2023, then surged by 97.11% to $14.6 million in 2024, then tumbled by 34.23% to $9.6 million in 2025, then jumped by 517.84% to $59.4 million in 2026.
• Per Business Quant, the three latest MIRM Accounts Payables figures stand at $59.4 million (Q1 2026), $9.6 million (Q4 2025), and $12.2 million (Q3 2025).